First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors

@article{Bylicki2019FirstLineTO,
  title={First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors},
  author={Olivier Bylicki and Helene Barazzutti and Nicolas Paleiron and Jacques Margery and Jean-Baptiste Assi{\'e} and Christos Choua{\"i}d},
  journal={BioDrugs},
  year={2019},
  volume={33},
  pages={159-171}
}
Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with molecularly targeted therapies, had been based on cytotoxic chemotherapy for a long time. Immune checkpoint inhibitors (ICIs), notably antibodies directed against programmed cell-death protein-1 (PD-1) and its ligand (PD-L1) have transformed therapeutic standards in thoracic oncology. These ICIs are now the reference second-line treatment and… CONTINUE READING
BETA
1
Twitter Mention

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

  • The New England journal of medicine
  • 2018
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

  • The New England journal of medicine
  • 2017
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Pembrolizumab for the treatment of non-small cell lung cancer.

  • Expert opinion on biological therapy
  • 2016
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL